Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | melanin-concentrating hormone receptor 1 | Starlite/ChEMBL | References |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Mycobacterium ulcerans | hypothetical protein | 0.0086 | 1 | 0.5 |
Mycobacterium tuberculosis | Possible oxidoreductase | 0.0086 | 1 | 0.5 |
Schistosoma mansoni | monoxygenase | 0.0086 | 1 | 1 |
Mycobacterium tuberculosis | Probable oxidoreductase | 0.0086 | 1 | 0.5 |
Mycobacterium ulcerans | FAD-linked oxidoreductase | 0.0086 | 1 | 0.5 |
Toxoplasma gondii | FAD binding domain-containing protein | 0.0086 | 1 | 0.5 |
Leishmania major | hypothetical protein, conserved | 0.0086 | 1 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0086 | 1 | 1 |
Echinococcus multilocularis | protein MICAL 3 | 0.0086 | 1 | 1 |
Trypanosoma cruzi | Monooxygenase, putative | 0.0086 | 1 | 0.5 |
Mycobacterium ulcerans | membrane-associated oxidoreductase | 0.0086 | 1 | 0.5 |
Toxoplasma gondii | FAD binding domain-containing protein | 0.0086 | 1 | 0.5 |
Mycobacterium tuberculosis | Possible oxidoreductase | 0.0086 | 1 | 0.5 |
Plasmodium falciparum | FAD-dependent monooxygenase, putative | 0.0086 | 1 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0075 | 0.7913 | 0.7913 |
Entamoeba histolytica | hypothetical protein | 0.0036 | 0 | 0.5 |
Entamoeba histolytica | hypothetical protein | 0.0036 | 0 | 0.5 |
Mycobacterium tuberculosis | Probable oxidoreductase | 0.0086 | 1 | 0.5 |
Trypanosoma cruzi | hypothetical protein, conserved | 0.0086 | 1 | 0.5 |
Mycobacterium tuberculosis | Possible oxidoreductase | 0.0086 | 1 | 0.5 |
Entamoeba histolytica | hypothetical protein | 0.0036 | 0 | 0.5 |
Plasmodium vivax | FAD-dependent monooxygenase, putative | 0.0086 | 1 | 0.5 |
Brugia malayi | Corticotropin releasing factor receptor 2 precursor, putative | 0.0049 | 0.2762 | 1 |
Mycobacterium ulcerans | hypothetical protein | 0.0086 | 1 | 0.5 |
Mycobacterium leprae | possibleputative FAD-linked oxidoreductase | 0.0086 | 1 | 0.5 |
Mycobacterium ulcerans | oxidoreductase | 0.0086 | 1 | 0.5 |
Echinococcus multilocularis | ubiquinone biosynthesis monooxygenase COQ6 | 0.0086 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0086 | 1 | 1 |
Leishmania major | hypothetical protein, conserved | 0.0086 | 1 | 0.5 |
Mycobacterium ulcerans | FAD-dependent oxidoreductase | 0.0086 | 1 | 0.5 |
Plasmodium vivax | hypothetical protein, conserved | 0.0086 | 1 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | 2-polyprenyl-6-methoxyphenol 4-hydroxylase | 0.0086 | 1 | 0.5 |
Mycobacterium ulcerans | oxidoreductase GMC-type | 0.0086 | 1 | 0.5 |
Mycobacterium ulcerans | oxidoreductase | 0.0086 | 1 | 0.5 |
Entamoeba histolytica | hypothetical protein | 0.0036 | 0 | 0.5 |
Echinococcus granulosus | ubiquinone biosynthesis monooxygenase COQ6 | 0.0086 | 1 | 1 |
Mycobacterium ulcerans | hypothetical protein | 0.0086 | 1 | 0.5 |
Trypanosoma brucei | kynurenine 3-monooxygenase, putative | 0.0086 | 1 | 1 |
Brugia malayi | Calcitonin receptor-like protein seb-1 | 0.0049 | 0.2762 | 1 |
Echinococcus granulosus | protein MICAL 3 | 0.0086 | 1 | 1 |
Trypanosoma brucei | Monooxygenase, putative | 0.0086 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
CL (ADMET) | 0 | Metabolic stability assessed as intrinsic clearance in human liver microsomes | ChEMBL. | 17532215 |
IC50 (functional) | Antagonist activity at human MCHR1 expressed in HEK293 cells assessed as [35S]GTPgammaS accumulation | ChEMBL. | 17532215 | |
IC50 (functional) | 0 | Antagonist activity at human MCHR1 expressed in HEK293 cells assessed as [35S]GTPgammaS accumulation | ChEMBL. | 17532215 |
IC50 (binding) | = 0.571 uM | Displacement of [125I]MCH from human MCHR1 expressed in HEK293 cells | ChEMBL. | 17532215 |
IC50 (binding) | = 0.571 uM | Displacement of [125I]MCH from human MCHR1 expressed in HEK293 cells | ChEMBL. | 17532215 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.